OSE Immunotherapeutics has shared phase 2 data on its neo-epitope vaccine candidate and Keytruda in ovarian cancer, linking maintenance use of the combination to improvements over best supportive care.
Morbi et tellus imperdiet, aliquam nulla sed, dapibus erat. Aenean dapibus sem non purus venenatis vulputate. Donec accumsan eleifend blandit. Nullam auctor ligula
Resonate Group, an ambitious Nigerian indigenous company with global aspirations, that aligns her vision with strategic intent to provide innovative solutions and services in Oil & Gas, Maritime, Manufacturing, Finance, Steel, Healthcare, and Supply Chain sectors of the Nigerian economy...
Copyright 2024 - All Rights Reserved By Resonate Group | Designed By Nysut Digital Studios